Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery

Fujiwara, Hidenori; Sakurai, Masahiro; Namai, Asako; Kawamura, Takae

doi:10.1007/s11748-008-0341-9

Cited by 42 publications

(26 citation statements)

References 36 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The utility of landiolol for preventing postoperative AF has been reported widely, [6][7][8] but this is the fi rst prospective randomized trial of postoperative landiolol and the dose (0.5 to 2 μg/kg/min) is the lowest for postoperative prophylactic administration. The ideal approach is to prevent postoperative AF without worsening hemodynamics, and this was achieved with ultra-low dose landiolol administration in this study.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Atrial Fibrillation with Ultra-Low Dose Landiolol after Off-Pump Coronary Artery Bypass Grafting

Nagaoka

Arai

Tamura

et al. 2014

ATCS

View full text Add to dashboard Cite

Purpose: Postoperative atrial fi brillation (AF) is a common complication of cardiac surgery that is associated with an increased incidence of other complications. The goal of this prospective randomized study was to evaluate the effect of ultra-low dose landiolol hydrochloride for prevention of AF after off-pump coronary artery bypass grafting (CABG). Methods: The subjects were 47 patients who underwent isolated CABG and were randomly divided into those who received landiolol from ICU admission until the beginning of oral drug intake (Group L) and those administered diltiazem hydrochloride over the same period (Group D). The incidence of AF within one week after surgery was examined as the primary endpoint. Heart rate, blood pressure, cardiac output, and other hemodynamic parameters were used as secondary endpoints. The rates of adverse events were also recorded. Results: The incidences of AF in the fi rst postoperative week were 4.8% and 27% in Groups L and D, respectively (p = 0.046). There were no differences in hemodynamic parameters between the Groups. In multivariate analysis, no factor emerged as a significant risk factor for postoperative AF. Two patients had adverse events of asthma and hypotension, respectively, in Group L. Conclusion: Ultra-low dose landiolol is effective for preventing AF after CABG without worsening hemodynamics.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of Atrial Fibrillation with Ultra-Low Dose Landiolol after Off-Pump Coronary Artery Bypass Grafting

Nagaoka

Arai

Tamura

et al. 2014

ATCS

View full text Add to dashboard Cite

show abstract

“…In a prospective randomized study, Sezai et al showed the preventive effect on POAF of using 48-h administration of intravenous landiolol (2 μg · kg -1 · min -1 ) from the beginning of the coronary artery bypass graft operation, 8 supporting the retrospective observation of Fujiwara et al 9 Now in Japan we are able to use 2 short-acting β-blockers, landiolol and esmolol, which have β1-selectivity. Sakamoto et al did not directly compare the 2 drugs, but they emphasized the few side effects with landiolol, noting that studies reporting the side effects of esmolol were not uncommon.…”

Section: Article P 1097mentioning

confidence: 78%

Intravenous Infusion of Ultra-Short-Acting β-Blocker for Postoperative Atrial Fibrillation Is the One of Choice

Amaki

2012

Circ J

View full text Add to dashboard Cite

“…29 In patients who undergo cardiac surgery, β-blockers are administered perioperatively without contraindications to reduce the incidence of postoperative atrial fibrillation. 9,30 Landiolol has been shown to inhibit postoperative atrial fibrillation after coronary artery bypass surgery, 9,14,15,[31][32][33] acute type A aortic dissection repair, 34 and heart valve surgery. 9,35 One study showed that landiolol was more effective than diltiazem for patients with postoperative atrial fibrillation after open heart surgery.…”

Section: Clinical Use Of Landiololmentioning

confidence: 99%

Clinical utility of landiolol for use in coronary CT angiography

Tomizawa¹,

Hayakawa²,

Inoh³

et al. 2015

RRCC

View full text Add to dashboard Cite

Although remarkable advancement in computed tomography (CT) has been achieved, heart rate control is important to maintain an optimal image quality in coronary CT angiography. Oral or intravenous β-blockers are used as premedication for this purpose. Landiolol was developed as a β-blocker with very high cardioselectivity (β1/β2 =255) and short half-life (4 minutes). In this review, we report the pharmacological features and usage of landiolol and also its effects on heart rate and image quality in coronary CT angiography. In addition, we discuss the safety of landiolol.

show abstract

Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery

Abstract: Intraoperative and perioperative administration of low-dose landiolol has a preventive effect on the appearance of atrial fibrillation after CABG surgery.

Cited by 42 publications

References 36 publications

Prevention of Atrial Fibrillation with Ultra-Low Dose Landiolol after Off-Pump Coronary Artery Bypass Grafting

Prevention of Atrial Fibrillation with Ultra-Low Dose Landiolol after Off-Pump Coronary Artery Bypass Grafting

Intravenous Infusion of Ultra-Short-Acting β-Blocker for Postoperative Atrial Fibrillation Is the One of Choice

Clinical utility of landiolol for use in coronary CT angiography

Contact Info

Product

Resources

About